Clinical trials: Thyroid Carcinoma
Cancer
Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer
RATIONALE: Hepatic arterial infusion uses a catheter to deliver anticancer substances directly into the liver. Drugs used in chemotherapy, such as melphalan, work in different ways to stop tumor cells from dividing so they stop…
- Trial name
- NCT00096083
- Testing
- isolated perfusion, melphalan
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Delcath Systems Inc.
Differentiated Thyroid Cancer
Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake For rhTSH In Post-thyroidectomized Patients
Phase I/II Clinical Trial of Dose-tolerance, Pharmacokinetics and Iodine Uptake Effects For Recombinant Human Thyroid Stimulating Hormone In Post-thyroidectomized Patients
- Trial name
- NCT04137185
- Testing
- Recombinant Human Thyroid Stimulating Hormone for Injection
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Thyroid Cancer, Thyroid Nodules
ctDNA in Patients With Thyroid Nodules
When the DNA inside of human cells undergoes certain alterations (mutations), the cells may develop into a cancer. The cancer cells may shed this DNA into the blood stream.
- Conditions
- Thyroid Cancer, Thyroid Nodules, Thyroid Adenoma, Thyroiditis
- Trial name
- NCT02778412
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Pathway Genomics
Thyroid Nodule, Thyroid Cancer
Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses
This proposal is designed as a pilot study for the use of laser ablation for local control of symptomatic (e.g compressive) benign thyroid masses in 20 patients.
- Conditions
- Thyroid Nodule, Thyroid Cancer, Thyroid Neoplasms, Nodular Goiter
- Trial name
- NCT00615537
- Testing
- Laser Ablation of Thyroid Nodule
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- BioTex, Inc.
Papillary Thyroid Microcarcinoma
Radiofrequency Ablation Treatment of Low-Risk Papillary Thyroid Carcinomas
Researchers in this study aim to prove the safety and efficacy of radiofrequency ablation in the treatment of a carefully selected low-risk papillary thyroid microcarcinoma patient group.
- Trial name
- NCT07506161
- Testing
- Radiofrequency ablation alone
- Where
- Hungary
- Volunteers
- 27 people
- Sponsor
- Premier G Med Cardio Kft
Thyroid Cancer
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with…
- Trial name
- NCT00124527
- Testing
- Irofulven + capecitabine
- Where
- 10 sites in United States, Argentina and 4 more
- Volunteers
- 35 people
- Sponsor
- Eisai Inc.
Differentiated Thyroid Cancer
A Phase 3 Study of Donafenib in Patients With Radioiodine-refractory Differentiated Thyroid Cancer
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study to compare the progression free survival, overall response rate (ORR) and safety of participants treated with Donafenib 0.3g Bid by continuous oral…
- Trial name
- DTC (NCT03602495)
- Testing
- Donafenib
- Where
- China
- Volunteers
- 204 people
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Thyroid Cancer, Colon Cancer
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
This is a phase 1b/2 study to evaluate the safety, tolerability, and efficacy of ETBX-011 vaccine used in combination with ALT-803 in subjects with locally advanced or metastatic CEA-expressing cancers whose tumor has recurred…
- Conditions
- Thyroid Cancer, Colon Cancer, Ovarian Cancer, Breast Cancer
- Trial name
- NCT03127098
- Testing
- ETBX-011, ALT-803
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- NantCell, Inc.
Thyroid Cancer
Efficacy and Tolerability of ZD6474 in Patients With Thyroid Cancer
The purpose of this open label, two stage, phase II study is to evaluate the efficacy and tolerability of ZD6474 in patients with locally advanced or metastatic hereditary medullary thyroid carcinoma.
- Trial name
- NCT00098345
- Testing
- ZD6474 (vandetanib)
- Where
- 6 sites in United States, France
- Volunteers
- 40 people
- Sponsor
- Genzyme, a Sanofi Company
Cancer, Solid Tumor
A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101)
This clinical trial evaluated the safety and efficacy of KVA12123, subsequently designated TBS-2025, alone or combined with pembrolizumab in patients with advanced solid tumors.
- Conditions
- Cancer, Solid Tumor, Melanoma, Carcinoma
- Trial name
- NCT05708950
- Testing
- KVA12123 - Dose Escalation, KVA12123 Plus Pembrolizumab - Dose Escalation, KVA12123 - Dose Expansion
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Kineta Inc.
Thyroid Cancer
Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer
The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid…
- Trial name
- EXAM (NCT00704730)
- Testing
- XL184
- Where
- 113 sites in United States, Austria and 22 more
- Volunteers
- 330 people
- Sponsor
- Exelixis
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Thyroid Carcinoma
Study of Sulfatinib in Treating Advanced Medullary Thyroid Carcinoma and Iodine-refractory Differentiated Thyroid Carcinoma
A multi-center , opened, Phase II study to assess the efficacy and safety of Sulfatinib 300 mg Sulfatinib in advanced Medullary Thyroid Carcinoma ( MTC) and iodine-refractory differentiated thyroid carcinoma (DTC).
- Trial name
- NCT02614495
- Testing
- Surufatinib
- Where
- 2 sites in China
- Volunteers
- 66 people
- Sponsor
- Hutchison Medipharma Limited
Anaplastic Thyroid Cancer
Evaluating Trends in Anaplastic Thyroid Cancer Patients' Clinical Study Experiences
Clinical trials can sometimes favor certain demographic groups. Additionally, there is limited research that delves into the factors that influence participation in clinical study, both positive and negative.
- Trial name
- NCT05819593
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Thyroid Carcinoma
Sorafenib Phase II Study for Japanese Anaplastic or Medullary Thyroid Carcinoma Patients
The objectives of this study are to evaluate safety, efficacy and pharmacokinetics of sorafenib for the treatment of Japanese patients with anaplastic thyroid carcinoma (ATC) or locally advanced or metastatic medullary thyroid…
- Trial name
- NCT02114658
- Testing
- Sorafenib (Nexavar,BAY43-9006)
- Where
- 5 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Bayer
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Advanced or Metastatic Solid Tumors
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
To evaluate the efficacy of naporafenib administered with trametinib in patients with rat sarcoma viral oncogene (RAS) Q61X solid tumors To evaluate the safety and tolerability of naporafenib administered with trametinib in…
- Trial name
- SEACRAFT-1 (NCT05907304)
- Testing
- Naporafenib, Trametinib
- Where
- 29 sites in United States, Australia and 3 more
- Volunteers
- 86 people
- Sponsor
- Erasca, Inc.
Carcinoma, Non-Small-Cell Lung, Thyroid Neoplasms
A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment
The main purpose of this study is to learn more about the safety, side effects, and effectiveness of LOXO-260. LOXO-260 may be used to treat cancer that has a change in a particular gene (known as the RET gene).
- Trial name
- NCT05241834
- Testing
- LOXO-260
- Where
- 16 sites in United States, France
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
Solid Tumors
Study of SNH-118110 in Advanced Solid Tumors
This is a multicenter, open-label, Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of SNH-118110 administered orally.
- Trial name
- SNH-118110 (NCT07649200)
- Testing
- SNH-118110 Soft Capsules
- Where
- China
- Volunteers
- 240 people
- Sponsor
- ScinnoHub Pharmaceutical Co., Ltd.
Thyroid Neoplasms
Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer
The primary purpose is to determine how effective AG-013736 is in shrinking thyroid cancer that is resistant to radioactive iodine
- Trial name
- NCT00389441
- Testing
- AG-013736
- Where
- 26 sites in United States, Canada and 7 more
- Volunteers
- 52 people
- Sponsor
- Pfizer